Prognosis in Behcet's disease.
A retrospective clinical study made to determine the course and prognosis of the disease in 51 cases of Behçet's disease, with a follow-up of at least one year (average five years, range 1 to 15 years), showed that 45% of the eyes kept visual acuities of 1/10 or less, and 44% 8/10 or better, four years after the onset of the ocular symptoms. Ten years later, some 50% of the eyes had visual acuities of 1/10 or less and 32% had acuities of 8/10 or better. In the group of patients who were treated early with chlorambucil, the eye prognosis was significantly improved.
D000293:Adolescent; D000328:Adult; D001528:Behcet Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D002493:Central Nervous System Diseases / Q000150:complications; D002699:Chlorambucil / Q000009:adverse effects / Q000627:therapeutic use; D005128:Eye Diseases / Q000150:complications; D005260:Female; D006680:HLA Antigens / Q000032:analysis; D015235:HLA-B Antigens; D059949:HLA-B51 Antigen; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012871:Skin Diseases / Q000150:complications; D013256:Steroids / Q000627:therapeutic use; D013281:Stomatitis, Aphthous / Q000150:complications; D014652:Vascular Diseases / Q000150:complications; D014792:Visual Acuity / Q000187:drug effects
D006680:HLA Antigens; D015235:HLA-B Antigens; C035270:HLA-B5 antigen; D059949:HLA-B51 Antigen; D013256:Steroids; D002699:Chlorambucil